Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective HDAC6 inhibitors is important to minimise the side effects of pan inhibition. Thus, new class of hydroxamic acid-based derivatives were designed on structural basis to perform preferential activity a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kassab, Shaymaa E., Mowafy, Samar, Alserw, Aya M., Seliem, Joustin A., El-Naggar, Shahenda M., Omar, Nesreen N., Awad, Mohamed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522981/
https://www.ncbi.nlm.nih.gov/pubmed/31072216
http://dx.doi.org/10.1080/14756366.2019.1613987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522981/
https://www.ncbi.nlm.nih.gov/pubmed/31072216
http://dx.doi.org/10.1080/14756366.2019.1613987

Ejemplares similares